CareDx Is At $1,550 A Transplant Test And Still Chasing $2,000, CFO Says
The fourth-quarter model assumes $1,550 per transplant test, and management sees NavDx pricing climbing toward $1,000 or more.
CareDx, which sells blood tests that monitor transplant recipients for rejection, is still working toward a three-year goal of $2,000 in revenue per solid-organ transplant test, Chief Operating Officer and CFO Keith Kennedy told analysts on the company's third-quarter earnings call. The fourth-quarter model assumes $1,550 of accrued revenue per test, he said.
The $2,000 transplant goal
Kennedy said the company had set a three-year target of $2,000 per test and that the team is still "rolling on getting to 2,000 per test." He stressed that the goal covers solid organ transplant only, not oncology.
Transplant revenue per test excluding specialty oncology was $1,514 in the third quarter, up 15% from a year earlier, he said. The fourth-quarter model puts transplant at about $1,680 per test, made up of $1,550 of accrued revenue and $130 of out-of-period revenue, meaning collections on earlier periods.
Transplant testing volume grew 21% in the quarter to 50,750 tests. Revenue for the quarter was $139 million, up 39%, and adjusted EBITDA doubled to $30 million from $15 million.
NavDx pricing room
CareDx bought NavDx, a test for HPV-driven head and neck cancers, and closed the deal on July 1. NavDx revenue per test was $823 in the quarter, 6% above the company's $775 forecast, Kennedy said. The fourth-quarter model assumes $825.
Asked about the outlook, Kennedy said the company expects to "see price appreciation up to $1,000 or higher over time." He noted that the Medicare price for the test is $1,800. NavDx moved onto CareDx's own billing system on October 1.
Kennedy called NavDx pricing an upward story but said the company is not prepared to quantify it yet. He said management hopes to say more on the fourth-quarter call.
Guidance and 2027 modeling
CareDx raised its 2026 revenue guidance by $30 million to $520 million to $530 million, and its adjusted EBITDA guidance by $23 million to $90 million to $100 million. It ended the quarter with $250 million in cash and no debt.
CEO John Hanna said the company is not giving 2027 guidance. For modeling, he pointed to earlier targets of 15% annual growth in solid organ transplant and 30% to 40% growth for NavDx through 2027, and suggested holding the fourth-quarter revenue-per-test figures steady.
Management said it will address 2027 expectations, including NavDx pricing, on its fourth-quarter call.
Sources
- CareDx Non-GAAP EPS of $0.70 beats by $0.44, revenue of $139M beats by $17.04M (NASDAQ:CDNA) | Seeking Alpha — seekingalpha.com
- CareDx: Q3 Earnings Snapshot — Associated Press
- CareDx: Q3 Earnings Snapshot – WTOP News — wtop.com
- CareDx: Q3 Earnings Snapshot | wusa9.com — Associated Press
- CareDx: Q3 Earnings Snapshot | king5.com — Associated Press